MNDA

Athira Pharma Reports Full Year 2023 Financial Results and Pipeline and Business Updates

Retrieved on: 
Thursday, February 22, 2024

BOTHELL, Wash., Feb. 22, 2024 (GLOBE NEWSWIRE) -- Athira Pharma, Inc. (NASDAQ: ATHA), a late clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health and slow neurodegeneration, today reported financial results for the year ended December 31, 2023, and reviewed recent pipeline and business updates.

Key Points: 
  • In December 2023, the Company announced encouraging results from the exploratory Phase 2 SHAPE clinical trial to evaluate fosgonimeton in patients with Parkinson's disease dementia and dementia with Lewy bodies.
  • In May 2023, Athira selected the 40 mg dose for further development and potential regulatory approval.
  • In January 2024, Athira completed enrollment of the LIFT-AD study, randomizing approximately 315 patients in the primary analysis population.
  • In December 2023, Athira announced encouraging results from the exploratory SHAPE Phase 2 clinical trial of fosgonimeton for the potential treatment of Parkinson's disease dementia and dementia with Lewy bodies.

Metabolon and Sheffield Institute for Translational Neuroscience Join Forces to Propel ALS Research and Biomarker Discovery

Retrieved on: 
Tuesday, January 23, 2024

MORRISVILLE, N.C., Jan. 23, 2024 /PRNewswire/ -- Metabolon, Inc., the global leader in providing metabolomics solutions advancing a wide variety of life science research, diagnostic, therapeutic development, and precision medicine applications, today announced a strategic partnership with the Sheffield Institute for Translational Neuroscience (SITraN) and A Multicentre Biomarker Resource Strategy in ALS (AMBRoSIA). The collaboration aims to explore novel pathogenic mechanisms of ALS that may expand therapeutic possibilities to a patient population in need of additional treatment options.

Key Points: 
  • Motor neuron diseases (MND), which include ALS, are progressive disorders that affect voluntary muscle control.
  • Currently, there is no cure for these diseases, and approximately 80% of people with ALS die within two to five years of diagnosis.
  • "Metabolon is thrilled to collaborate with SITraN, a leading institution in translational neuroscience, and AMBRoSIA.
  • Together, we aim to drive significant progress in ALS research and biomarker discovery, bringing us closer to effective diagnostic and therapeutic solutions for this challenging disease," said Karl Bradshaw, Chief Business Officer at Metabolon.

Metabolon and Sheffield Institute for Translational Neuroscience Join Forces to Propel ALS Research and Biomarker Discovery

Retrieved on: 
Tuesday, January 23, 2024

MORRISVILLE, N.C., Jan. 23, 2024 /PRNewswire/ -- Metabolon, Inc., the global leader in providing metabolomics solutions advancing a wide variety of life science research, diagnostic, therapeutic development, and precision medicine applications, today announced a strategic partnership with the Sheffield Institute for Translational Neuroscience (SITraN) and A Multicentre Biomarker Resource Strategy in ALS (AMBRoSIA). The collaboration aims to explore novel pathogenic mechanisms of ALS that may expand therapeutic possibilities to a patient population in need of additional treatment options.

Key Points: 
  • Motor neuron diseases (MND), which include ALS, are progressive disorders that affect voluntary muscle control.
  • Currently, there is no cure for these diseases, and approximately 80% of people with ALS die within two to five years of diagnosis.
  • "Metabolon is thrilled to collaborate with SITraN, a leading institution in translational neuroscience, and AMBRoSIA.
  • Together, we aim to drive significant progress in ALS research and biomarker discovery, bringing us closer to effective diagnostic and therapeutic solutions for this challenging disease," said Karl Bradshaw, Chief Business Officer at Metabolon.

Athira Pharma Announces Upcoming Presentation at Motor Neurone Disease Association’s 34ᵗʰ International Symposium on ALS/MND

Retrieved on: 
Tuesday, November 28, 2023

BOTHELL, Wash., Nov. 28, 2023 (GLOBE NEWSWIRE) -- Athira Pharma, Inc. (NASDAQ: ATHA), a late clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health and slow neurodegeneration, today announced that a symposium presentation highlighting data from preclinical studies of ATH-1105 as a potential treatment candidate for amyotrophic lateral sclerosis (ALS) will be delivered at the upcoming Motor Neurone Disease Association (MNDA) 34th International Symposium on ALS/MND , to be held December 6 – 8, 2023 in Basel, Switzerland.

Key Points: 
  • BOTHELL, Wash., Nov. 28, 2023 (GLOBE NEWSWIRE) -- Athira Pharma, Inc. (NASDAQ: ATHA), a late clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health and slow neurodegeneration, today announced that a symposium presentation highlighting data from preclinical studies of ATH-1105 as a potential treatment candidate for amyotrophic lateral sclerosis (ALS) will be delivered at the upcoming Motor Neurone Disease Association (MNDA) 34th International Symposium on ALS/MND , to be held December 6 – 8, 2023 in Basel, Switzerland.
  • Title: ATH-1105, a small molecule positive modulator of the neurotrophic hepatocyte growth factor system, is neuroprotective when administered prophylactically, therapeutically or in combination with riluzole in the prp-TDP-43 A315T mouse model of ALS
    “We look forward to the presentation of these data, which highlight the potential of ATH-1105 as a treatment for ALS and add to the growing body of scientific and clinical data that support the potential benefits of our small molecule therapeutic candidates targeting the neurotrophic HGF system as novel treatments for neurodegenerative diseases,” stated Mark Litton, Ph.D., President and Chief Executive Officer of Athira.
  • “These data, which include preclinical data showing prolonged survival and demonstrating consistent improvements in motor function, nerve function, biomarkers and nerve morphology in a transgenic mouse model of ALS, strongly support confidence in our plans to advance this program into human clinical studies in the first half of 2024.”

Mitsubishi Tanabe Pharma America Announces Presentations in ALS at 34th International Symposium on ALS/MND

Retrieved on: 
Tuesday, December 5, 2023

JERSEY CITY, N.J., Dec. 5, 2023 /PRNewswire/ -- Mitsubishi Tanabe Pharma America, Inc. (MTPA) today announced that four abstracts in amyotrophic lateral sclerosis (ALS) will be presented at the Motor Neurone Disease Association (MNDA) 34th International Symposium on ALS/MND, being held in Basel, Switzerland, from December 6-8.

Key Points: 
  • JERSEY CITY, N.J., Dec. 5, 2023 /PRNewswire/ -- Mitsubishi Tanabe Pharma America, Inc. (MTPA) today announced that four abstracts in amyotrophic lateral sclerosis (ALS) will be presented at the Motor Neurone Disease Association (MNDA) 34th International Symposium on ALS/MND, being held in Basel, Switzerland, from December 6-8.
  • MTPA's posters will be displayed during poster sessions held in the Event Halle on December 6 and 7.
  • A Preliminary Analysis of Oral Edaravone-Treated Patients with Amyotrophic Lateral Sclerosis Enrolled in a US-Based Administrative Claims Database (Malgorzata Ciepielewska, M.S.
  • ; State University of New York Upstate Medical University)
    Poster Session B (Part 1), 5:45 p.m. – 6:45 p.m. CET, Dec. 7

Mandalay Resources Provides Target Release Date for Second Quarter 2023 Financial Results and Conference Call

Retrieved on: 
Thursday, August 3, 2023

TORONTO, Aug. 3, 2023 /PRNewswire/ - Mandalay Resources Corporation ("Mandalay" or "the Company") (TSX: MNDA) (OTCQB: MNDJF) today announced that its second quarter 2023 financial results will be released after market close on August 09, 2023, followed by a conference call and webcast with Frazer Bourchier, President and Chief Executive Officer of Mandalay, for investors and analysts on Aug 10, 2023, at 8:00 AM (Toronto time).

Key Points: 
  • TORONTO, Aug. 3, 2023 /PRNewswire/ - Mandalay Resources Corporation ("Mandalay" or "the Company") (TSX: MNDA) (OTCQB: MNDJF) today announced that its second quarter 2023 financial results will be released after market close on August 09, 2023, followed by a conference call and webcast with Frazer Bourchier, President and Chief Executive Officer of Mandalay, for investors and analysts on Aug 10, 2023, at 8:00 AM (Toronto time).
  • Analysts and interested investors are recommended to join the conference call by registering your name and phone number at the following URL to receive an instant automated call on your phone, to avoid any wait time to talk to an operator by clicking here .
  • You may also join by using the following dial-in numbers for an operator:

Mandalay Resources Provides Target Release Date for Second Quarter 2023 Financial Results and Conference Call

Retrieved on: 
Thursday, August 3, 2023

TORONTO, Aug. 3, 2023 /PRNewswire/ -- Mandalay Resources Corporation ("Mandalay" or "the Company") (TSX: MNDA) (OTCQB: MNDJF) today announced that its second quarter 2023 financial results will be released after market close on August 09, 2023, followed by a conference call and webcast with Frazer Bourchier, President and Chief Executive Officer of Mandalay, for investors and analysts on Aug 10, 2023, at 8:00 AM (Toronto time).

Key Points: 
  • TORONTO, Aug. 3, 2023 /PRNewswire/ -- Mandalay Resources Corporation ("Mandalay" or "the Company") (TSX: MNDA) (OTCQB: MNDJF) today announced that its second quarter 2023 financial results will be released after market close on August 09, 2023, followed by a conference call and webcast with Frazer Bourchier, President and Chief Executive Officer of Mandalay, for investors and analysts on Aug 10, 2023, at 8:00 AM (Toronto time).
  • Analysts and interested investors are recommended to join the conference call by registering your name and phone number at the following URL to receive an instant automated call on your phone, to avoid any wait time to talk to an operator by clicking here .
  • You may also join by using the following dial-in numbers for an operator:

Mitsubishi Tanabe Pharma America Presents REFINE-ALS Biomarker Study Details at Virtual 32nd International Symposium on ALS/MND

Retrieved on: 
Friday, December 10, 2021

Details were presented as part of theMotor Neurone Disease Association (MNDA)32nd International Symposium on ALS/MND, being held virtually December 7-10.

Key Points: 
  • Details were presented as part of theMotor Neurone Disease Association (MNDA)32nd International Symposium on ALS/MND, being held virtually December 7-10.
  • The U.S. Food and Drug Administration (FDA) approved RADICAVA (edaravone) IV on May 5, 2017 as a treatment for amyotrophic lateral sclerosis (ALS).1 Edaravone was discovered and developed for ALS by Mitsubishi Tanabe Pharma Corporation (MTPC) and Mitsubishi Tanabe Pharma Development America, Inc. (MTDA), commercialized in the U.S. by Mitsubishi Tanabe Pharma America, Inc.
  • You may report side effects to Mitsubishi Tanabe Pharma America, Inc. at 1-888-292-0058 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch .
  • About Mitsubishi Tanabe Pharma America, Inc.
    Based in Jersey City, N.J., Mitsubishi Tanabe Pharma America, Inc. (MTPA) is a wholly-owned subsidiary of Mitsubishi Tanabe Pharma Corporation's (MTPC) 100 percent owned U.S. holding company, Mitsubishi Tanabe Pharma Holdings America, Inc.

Mitsubishi Tanabe Pharma America Showcases Breadth of ALS Research at Virtual 32nd International Symposium on ALS/MND

Retrieved on: 
Wednesday, December 1, 2021

The U.S. Food and Drug Administration (FDA) approved RADICAVA(edaravone) IV on May 5, 2017 as a treatment for amyotrophic lateral sclerosis (ALS).1Edaravone was discovered and developed for ALS by Mitsubishi Tanabe Pharma Corporation (MTPC) and Mitsubishi Tanabe Pharma Development America, Inc. (MTDA), commercialized in the U.S. by Mitsubishi Tanabe Pharma America, Inc.

Key Points: 
  • The U.S. Food and Drug Administration (FDA) approved RADICAVA(edaravone) IV on May 5, 2017 as a treatment for amyotrophic lateral sclerosis (ALS).1Edaravone was discovered and developed for ALS by Mitsubishi Tanabe Pharma Corporation (MTPC) and Mitsubishi Tanabe Pharma Development America, Inc. (MTDA), commercialized in the U.S. by Mitsubishi Tanabe Pharma America, Inc.
  • About Mitsubishi Tanabe Pharma America, Inc.
    Based in Jersey City, N.J., Mitsubishi Tanabe Pharma America, Inc. (MTPA) is a wholly-owned subsidiary of Mitsubishi Tanabe Pharma Corporation's (MTPC) 100 percent owned U.S. holding company, Mitsubishi Tanabe Pharma Holdings America, Inc.
  • The U.S. headquarters of Mitsubishi Tanabe Pharma Development America, Inc. (MTDA) is located in Jersey City, New Jersey.
  • MTDA is a wholly-owned subsidiary of Mitsubishi Tanabe Pharma Corporation's 100 percent-owned U.S. holding company, Mitsubishi Tanabe Pharma Holdings America, Inc. MTDA is dedicated to research and develop innovative pharmaceutical products that address the unmet medical needs of patients.

Mental and Nervous Long-Term Disability Claims for Healthcare Professionals Jumped Significantly in 2020

Retrieved on: 
Tuesday, August 17, 2021

Mental and Nervous disability claims filed in 2020 (11.5% of total claims) reflected an 85.8% increase over those filed in 2019 (6.7% of total claims).

Key Points: 
  • Mental and Nervous disability claims filed in 2020 (11.5% of total claims) reflected an 85.8% increase over those filed in 2019 (6.7% of total claims).
  • A 2020 North Carolina State University study found that on average, healthcare professionals reported enough symptoms of depression to be diagnosed with clinical depression.
  • According to the tally of long-term disability claims submitted in 2020 by healthcare professionals insured by MGIS, the top five reasons for filing the claims were:
    (tie) Nervous System (Parkinson's disease, multiple sclerosis)
    "The increased incidence of mental health disabilities last year highlights the importance of comprehensive disability insurance for healthcare professionals," Brunken explained.
  • MGIS is a leading national insurance program manager that builds and manages specialized insurance programs for healthcare professionals.